New Five-Year Lecanemab Data Presented at CTAD 2026 Show Sustained Benefits in Early Alzheimer's Disease
· GlobeWire Daily Business Desk · Source: www.prnewswire.com

Image: Eisai Inc. · Photo source · Resized and letterboxed to 16:9; no AI generation
New five-year data from the Clarity AD study long-term extension were presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, showing continued benefits of continuous lecanemab treatment for early Alzheimer's disease. According to Eisai and Biogen, the findings indicate that ongoing treatment extends the time patients remain in the early stages of the disease compared to natural history data.
Study Findings and Clinical Outcomes
Researchers reported that among patients receiving five years of continuous treatment, differences in mean changes from baseline in clinical dementia rating scales compared favorably with historical datasets such as ADNI and BioFINDER. Specifically, lecanemab reduced the relative risk of progressing to subsequent disease stages compared to ADNI reference data. Furthermore, subset analyses of patients with low levels of brain tau indicated that a majority showed no clinical decline or experienced improvement on specific cognitive and daily living scales at five years.
Safety Profile and Treatment Context
No new safety signals were identified during the five-year evaluation period. Amyloid-related imaging abnormalities with edema or effusion (ARIA-E) occurred most frequently within the initial six-month window, with incidence rates decreasing significantly in subsequent 12-month intervals.
Verification and Practical Implications
Readers can verify the original announcement through official press releases issued by Eisai and Biogen or by reviewing conference proceedings from CTAD 2026. Practical implications center on understanding long-term disease trajectories, though individual patient responses vary and ongoing physician consultation remains essential.
AI-assisted reporting; source claims are attributed and have not been independently verified.



